- Home
- HWC vs ZLAB Comparison
HWC vs ZLAB Comparison
Compare HWC & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HWC
- ZLAB
- Stock Information
- Founded
- HWC 1883
- ZLAB 2013
- Country
- HWC United States
- ZLAB China
- Employees
- HWC N/A
- ZLAB N/A
- Industry
- HWC Major Banks
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- HWC Finance
- ZLAB Health Care
- Exchange
- HWC Nasdaq
- ZLAB Nasdaq
- Market Cap
- HWC 4.3B
- ZLAB 3.6B
- IPO Year
- HWC N/A
- ZLAB 2017
- Fundamental
- Price
- HWC $60.39
- ZLAB $32.54
- Analyst Decision
- HWC Buy
- ZLAB Buy
- Analyst Count
- HWC 6
- ZLAB 5
- Target Price
- HWC $63.67
- ZLAB $54.28
- AVG Volume (30 Days)
- HWC 762.4K
- ZLAB 781.8K
- Earning Date
- HWC 07-15-2025
- ZLAB 08-05-2025
- Dividend Yield
- HWC 3.02%
- ZLAB N/A
- EPS Growth
- HWC 26.31
- ZLAB N/A
- EPS
- HWC 5.42
- ZLAB N/A
- Revenue
- HWC $1,401,299,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- HWC $10.91
- ZLAB $44.07
- Revenue Next Year
- HWC $5.65
- ZLAB $49.13
- P/E Ratio
- HWC $11.00
- ZLAB N/A
- Revenue Growth
- HWC 7.56
- ZLAB 43.72
- 52 Week Low
- HWC $43.90
- ZLAB $16.01
- 52 Week High
- HWC $62.40
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- HWC 62.68
- ZLAB 40.19
- Support Level
- HWC $59.52
- ZLAB $34.26
- Resistance Level
- HWC $62.24
- ZLAB $35.72
- Average True Range (ATR)
- HWC 1.41
- ZLAB 1.12
- MACD
- HWC 0.37
- ZLAB -0.54
- Stochastic Oscillator
- HWC 78.46
- ZLAB 3.83
About HWC Hancock Whitney Corporation
Hancock Whitney Corp operates bank offices and financial centers. The company offers a range of traditional and online banking services to commercial, small business, and retail customers, providing a variety of transaction and savings deposit products, treasury management services, secured and unsecured loan products (including revolving credit facilities), letters of credit, and similar financial guarantees. The Bank provides trust and investment management services to retirement plans, corporations, and individuals and provides its customers access to investment advisory and brokerage products.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.